Baird raised the firm’s price target on Regeneron to $800 from $756 and keeps a Neutral rating on the shares. The analyst raised his target on impressive Dupixent results in COPD and also raised his sales estimates upward based on the data.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN: